Press release
Immune-Mediated Inflammatory Diseases Market Top Players - Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.)
Immune-Mediated Inflammatory Diseases Market
According to the latest research by InsightAce Analytic, the Immune-Mediated Inflammatory Diseases Market is predicted to grow with a CAGR of 7.10% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2889
Immune-mediated inflammatory diseases (IMIDs) represent a class of interrelated conditions characterized by common inflammatory pathways driven by immune system dysregulation, although the precise underlying causes remain unidentified. These disorders stem from an overactive or malfunctioning immune response and are associated with elevated risks of morbidity, mortality, and long-term organ damage.
The global incidence of autoimmune diseases has been steadily rising, attributed to a combination of genetic predisposition and modifiable risk factors, including sedentary lifestyles and poor dietary habits. This upward trend is contributing to the continued expansion of the global IMID therapeutics market. As autoimmune conditions become increasingly prevalent, there is a growing demand for effective treatment options and therapeutic innovations to manage these complex, chronic disorders.
List of Prominent Players in the Immune-Mediated Inflammatory Diseases Market:
• Novartis AG
• Daiichi Sankyo Company, Limited
• Pfizer Inc.
• Abbvie Inc.
• Merck & Co Inc.
• Zydus Group
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• AstraZeneca
• Ampio Pharmaceuticals Inc.
• Eli Lilly
• Akorn Incorporated
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Drivers:
The global market for immune-mediated inflammatory diseases (IMIDs) is projected to experience sustained growth, primarily driven by the rising prevalence of chronic conditions such as psoriasis, Crohn's disease, and rheumatoid arthritis. Market expansion is further supported by the increasing adoption of advanced biologic therapies that offer targeted treatment approaches. Additionally, the growing availability of therapeutic options through diversified distribution channels-including specialty clinics, retail pharmacies, and digital health platforms-is enhancing patient access and fueling market momentum.
Challenges:
Despite favorable growth prospects, the market faces certain constraints. A significant challenge is the shortage of healthcare professionals trained in the administration of complex biologic treatments. Moreover, adverse effects associated with some therapies-such as dermatological reactions and complications linked to immunosuppressive drugs-may impact treatment adherence and patient outcomes. The COVID-19 pandemic further disrupted market performance, as healthcare systems worldwide deferred non-urgent procedures and diverted resources to pandemic response efforts, resulting in a temporary decline in market activity.
Regional Trends:
North America is anticipated to dominate the global IMID market in terms of revenue share, supported by a high incidence of autoimmune disorders, increasing demand for biologic therapeutics, and a strong emphasis on research and development of novel treatments. The approval and commercialization of innovative therapies and a growing requirement for immunosuppressive agents continue to drive regional market growth. Meanwhile, the Asia-Pacific region is witnessing accelerated growth, propelled by heightened awareness of autoimmune diseases, improved healthcare infrastructure, and ongoing technological advancements in the diagnosis and treatment of inflammatory conditions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2889
Recent Developments:
• In July 2024, AbbVie announced that the European Commission has sanctioned SKYRIZI® (risankizumab) for the treatment of elderly individuals with moderately to severely active ulcerative colitis (UC) who have experienced an inadequate response to, lost response to, or exhibited intolerance to conventional or biologic therapies.
Segmentation of Immune-Mediated Inflammatory Diseases Market-
By Indication-
• Asthma,
• Chronic Obstructive Pulmonary Diseases (COPD)
• Inflammatory Bowel Disease (IBD)
• Systemic Lupus Erythematosus (SLE)
• Rheumatoid Arthritis (RA)
• Psoriasis
• Others
By Treatment Type-
• Traditional Drugs
• Biologic Therapies
• Novel Therapies
By Route of Administration-
• Oral
• Parenteral
• Others
By End-Users-
• Hospitals
• Specialty Clinics
• Others
By Distribution Channel-
• Hospital Pharmacy
• Retail Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/immune-mediated-inflammatory-diseases-market/2889
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune-Mediated Inflammatory Diseases Market Top Players - Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.) here
News-ID: 4072148 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
T-cell Lymphoma Market Exclusive Report on Current Trends and Future Insights
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global T-cell Lymphoma Market By Lymphoma Type (Peripheral T-Cell Lymphoma (Cutaneous T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-Immuno-Blastic T-Cell Lymphoma, And Others (Intestinal T-Cell Lymphoma, Follicular T-Cell Lymphoma)) And T-Cell Lymphoblastic Lymphoma), Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, And Others (Antiviral Treatment, Etc.)- Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the…
Sprycel Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Sprycel Market- (By Demographic (Age, Gender, Income), By Psychographic (Lifestyle, Attitudes), By Behavioral, (Usage Rate, Compliance, Treatment), By Medical (Indication, Disease Stage)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Sprycel Market is valued at US$ 5.47 Bn in 2022, and it is expected to…
Spatial Omics Solutions Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Spatial Omics Solutions Market By Solution Type (Instruments, Consumables And Services), Sample Analyzed (DNA, RNA, And Protein Samples), Application (Diagnosis, Translation Research, Drug Discovery And Development, Single Cell Analysis, Cell Biology And Other Applications), End-User Segment (Academic And Research Institutions, Biopharmaceutical And Biotechnological Companies, Contract Research Organizations And Other)- Trends, Industry Competition Analysis, Revenue and…
Psoriasis Biosimilars Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Psoriasis Biosimilars Market - (By Drug Class (TNF-alpha inhibitors (Infliximab, Etanercept, Adalimumab), Other biosimilars), By Route of Administration (Subcutaneous, Intravenous, Oral, Topical), By Indication (Plaque psoriasis, Psoriatic arthritis, Other types), By Distribution Channel (Hospital pharmacies, Retail pharmacy chains, Online pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
